Abstract
This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Short-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 1/402), [corrected] abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis are (3.5%; 6/172) [corrected], abscess (1.2%; 2/172), oral candidiasis ...Continue Reading
References
Aug 1, 1992·Antimicrobial Agents and Chemotherapy·B H AckermanE B Eudy
Apr 1, 1984·Arthritis and Rheumatism·S van der LindenA Cats
Aug 1, 1995·British Journal of Rheumatology·L G KennedyA Calin
Aug 19, 2003·Annals of the Rheumatic Diseases·D BaetenE M Veys
Dec 3, 2003·Human Molecular Genetics·Andrew I RussellTimothy J Vyse
Jul 27, 2006·Arthritis and Rheumatism·W G DixonUNKNOWN British Society for Rheumatology Biologics Register
Jul 28, 2006·Arthritis Research & Therapy·Meliha C KapetanovicPierre Geborek
Feb 16, 2007·The British Journal of Dermatology·H-H LeeM Worm
Nov 6, 2007·Annals of the Rheumatic Diseases·V GerloniF Fantini
Mar 5, 2008·Rheumatology·L E KristensenP Geborek
Nov 21, 2008·Annals of the Rheumatic Diseases·T R D J RadstakeK Bendtzen
Apr 28, 2009·Rheumatology·Damien FouacheOlivier Vittecoq
Dec 3, 2009·Allergy·A VultaggioE Maggi
Apr 9, 2010·International Journal of Rheumatic Diseases·Parawee SuwannalaiS Janvitayanujit
May 1, 2008·Expert Review of Clinical Immunology·Andres PeisajovichTerry W Du Clos
May 25, 2010·Journal of Neurology·Antonio G Tristano
Aug 10, 2010·Core Evidence·Jonathan Kay, Mahboob U Rahman
Feb 1, 2011·Orvosi hetilap·Gabriella NagyZsuzsánna Károlyi
Feb 3, 2011·The Journal of Rheumatology·Gunnstein BaklandJohannes C Nossent
Mar 2, 2011·The American Journal of the Medical Sciences·Charles F Dillon, Rosemarie Hirsch
Jun 3, 2011·Arthritis Research & Therapy·Georg SchettPhillip G Conaghan
Jun 2, 2011·Arthritis and Rheumatism·Juergen BraunBruce Freundlich
Aug 14, 2012·Advances in Therapy·Machaon BonafedeShravanthi R Gandra
Oct 13, 2012·Pharmacogenomics·Qiang TongQing Cai
Mar 26, 2013·Clinics·Renata MiossiM Teresa C Caleiro
Sep 17, 2013·Lancet·Dominique BaetenWolfgang Hueber
Nov 7, 2013·Pharmacogenomics·Qiang TongDong-Bao Zhao
Mar 5, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Dewi GuellecAlain Saraux
Apr 11, 2014·Annals of the Rheumatic Diseases·Johanna CallhoffJoachim Listing
Citations
Dec 23, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joshua B FrenchHerbert L Bonkovsky
Aug 19, 2016·Expert Opinion on Biological Therapy·Sergio Fernandez-MartinezMd Elvira Casterá
Oct 14, 2016·Scandinavian Journal of Rheumatology·W GunasekeraR Sengupta
Jan 11, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael NurmohamedPaola Accossato
Nov 27, 2018·Journal of Clinical Pharmacology·Jakub Wroński, Piotr Fiedor
Mar 22, 2019·Journal of the Chinese Medical Association : JCMA·Yan ShenJian-Long Guan
May 10, 2020·Skeletal Radiology·Natalia GorelikSoterios Gyftopoulos
Aug 21, 2019·ELife·Lu YuThomas J Hannan